Results 61 to 70 of about 108,133 (341)

Experimental and clinical pharmacology - Incretin mimetics and enhancers: mechanisms of action [PDF]

open access: yes, 2008
The incretins are peptide hormones secreted from the gut in response to food. They increase the secretion of insulin. The incretin response is reduced in patients with type 2 diabetes, so drugs acting on incretins may improve glycaemic control. Incretins
Prins, Johannes B.
core   +1 more source

Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study

open access: yesBritish medical journal
Objective To determine whether the combined use of glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT-2) inhibitors is associated with a decreased risk of major adverse cardiovascular events and serious renal ...
N. Simms-Williams   +8 more
semanticscholar   +1 more source

Dapagliflozin prevents methylglyoxal‐induced retinal cell death in ARPE‐19 cells

open access: yesFEBS Open Bio, EarlyView.
Diabetic macular oedema is a diabetes complication of the eye, which may lead to permanent blindness. ARPE‐19 are human retinal cells used to study retinal diseases and potential therapeutics. Methylglyoxal is a compound increased in uncontrolled diabetes due to elevated blood glucose.
Naina Trivedi   +7 more
wiley   +1 more source

Glucagon-like peptide-1 receptor agonists in patients treated with antipsychotics

open access: yesEuropean Psychiatry, 2021
Introduction Glucagon-like peptide-1 (GLP-1) is an endogenous peptide that stimulates insulin secretion and decreases glucagon secretion. The use of GLP-1 receptor agonists (GLP-1RA) showed efficacy reducing the weight and glucose levels in patients ...
A. Delgado   +4 more
doaj   +1 more source

Extracellular loops 2 and 3 of the calcitonin receptor selectively modify agonist binding and efficacy. [PDF]

open access: yes, 2018
Class B peptide hormone GPCRs are targets for the treatment of major chronic disease. Peptide ligands of these receptors display biased agonism and this may provide future therapeutic advantage.
Andreassen   +70 more
core   +1 more source

A Novel CYP2E1 Inhibitor, 4‐Methyl‐5‐Acetylthiazole (Q11), Alleviates Obesity Via Modulating Adipose Inflammation and Mitochondrial Dysfunction

open access: yesAdvanced Science, EarlyView.
Obesity involves chronic inflammation and mitochondrial dysfunction. This study identifies cytochrome P450 2E1 (CYP2E1) as a novel inflammatory target in adipose tissue. Its activity increases in obese mice and correlates with inflammation and mitochondrial impairment.
Jinhuan Qiu   +10 more
wiley   +1 more source

Unraveling the obesity–asthma link: A new horizon with glucagon-like peptide-1 receptor agonists in a complex intersection of metabolism and airway disease

open access: yesJournal of International Medical Research
The global prevalence of obesity and asthma has escalated in parallel over recent decades, presenting an intertwined public health crisis. Obesity not only increases the risk of asthma development but also complicates its clinical course by altering ...
Francesco Menzella   +2 more
doaj   +1 more source

A Simplified Three‐Tailed N‐Alkyl Phosphoramidate Lipid Platform Enables Inguinal Adipose‐Accumulated mRNA Delivery for Anti‐Obesity Therapy

open access: yesAdvanced Science, EarlyView.
This study develops an mRNA therapy encoding a long‐acting GLP‐1/FGF21 fusion protein. A three‐tailed ionizable lipid engineered three‐component lipid nanoparticle delivers the mRNA to inguinal adipose tissue. In obese mice, this targeted, dual‐hormone treatment potently reduces body weight, fat mass, presenting a localized strategy for metabolic ...
Bin Ma   +10 more
wiley   +1 more source

Molecular regulation of hormone secretion, growth and apoptosis of GLP-1-producing cells [PDF]

open access: yes, 2013
Type 2 diabetes (T2D) spreads like an epidemic in today’s society, and there is a great need for new and improved treatments. T2D is characterized by hyperglycemia, resulting from impaired insulin production and insulin resistance in peripheral ...
Kappe, Camilla
core   +1 more source

Effectiveness of Pre‐Transplant Dual GLP‐1 Receptor Agonist and SGLT2 Inhibitor Therapy on All‐Cause Mortality in Organ Transplantation Candidates with Obesity and Type 2 Diabetes: a Target‐Trial Emulation

open access: yesAdvanced Science, EarlyView.
This target trial emulation in solid organ transplant candidates with obesity and type 2 diabetes evaluates whether pre‐transplant dual therapy with GLP‐1 receptor agonists plus SGLT2 inhibitors is associated with post‐transplant mortality and kidney graft outcomes compared with monotherapy or usual care, using multinational electronic health records ...
Yu‐Nan Huang   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy